| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
| 2020 | 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population | Yu M.-L.; PEI-JER CHEN ; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; CHEN-HUA LIU ; CHUN-JEN LIU ; Peng C.-Y.; Lin H.-C.; JIA-HORNG KAO ; Chuang W.-L. | Journal of the Formosan Medical Association | 50 | 47 | |
| 2020 | 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations | Yu M.-L.; PEI-JER CHEN ; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; CHEN-HUA LIU ; CHUN-JEN LIU ; Peng C.-Y.; Lin H.-C.; JIA-HORNG KAO ; Chuang W.-L. | Journal of the Formosan Medical Association | 50 | 45 | |
| 2020 | Ability of the post-operative ALBI grade to predict the outcomes of hepatocellular carcinoma after curative surgery | Cho W.-R.; Hung C.-H.; Chen C.-H.; Lin C.-C.; Wang C.-C.; Liu Y.-W.; Wu Y.-J.; Yong C.-C.; Chen K.-D.; YU-CHIEH TSAI ; Hu T.-H.; Tsai M.-C. | Scientific Reports | 17 | 14 | |
| 2013 | Accuracy of faecal occult blood test and Helicobacter pylori stool antigen test for detection of upper gastrointestinal lesions | YI-CHIA LEE ; HAN-MO CHIU ; TSUNG-HSIEN CHIANG ; Yen A.M.-F.; Chiu S.Y.-H.; Chen S.L.-S.; Fann J.C.-Y.; Yeh Y.-P.; Liao C.-S.; Hu T.-H.; CHIA-HUNG TU ; PING-HUEI TSENG ; CHIEN-CHUAN CHEN ; MEI-JYH CHEN ; JYH-MING LIOU ; WEI-CHIH LIAO ; YO-PING LAI ; Wang C.-P.; JENG-YUH KO ; HSIU-PO WANG ; Chiang H.; Lin J.-T.; Chen, Tony Hsiu Hsi ; MING-SHIANG WU | BMJ Open | 22 | 20 | |
| 2013 | Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study | Johnson P.J.; Qin S.; Park J.-W.; Poon R.T.P.; Raoul J.-L.; Philip P.A.; CHIH-HUNG HSU ; Hu T.-H.; Heo J.; Xu J.; Lu L.; Chao Y.; Boucher E.; Han K.-H.; Paik S.-W.; Robles-Aviña J.; Kudo M.; Yan L.; Sobhonslidsuk A.; Komov D.; Decaens T.; Tak W.-Y.; Jeng L.-B.; Liu D.; Ezzeddine R.; Walters I.; ANN-LII CHENG | Journal of Clinical Oncology | 609 | 589 | |
| 2013 | Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy | Chang K.-C.; Wu Y.-Y.; Hung C.-H.; Lu S.-N.; Lee C.-M.; Chiu K.-W.; Tsai M.-C.; Tseng P.-L.; Huang C.-M.; Cho C.-L.; Chen, Tony Hsiu Hsi ; Hu T.-H. | British Journal of Cancer | 54 | 48 | |
| 2021 | Community-Based Gastric Cancer Screening Coupled With a National Colorectal Cancer Screening Program: Baseline Results | YI-CHIA LEE ; TSUNG-HSIEN CHIANG ; HAN-MO CHIU ; MING-SHIANG WU ; Yeh, Yen-Po; Hsiu-Hsi Chen, Tony; Li-Sheng Chen S.; Ming-Fang Yen A.; Ching-Yuan Fann J.; Yueh-Hsia Chiu S.; Hsu C.-Y.; Chuang S.-L.; Chou K.-C.; Su W.-W.; Chen S.-T.; Liao C.-S.; Lin Y.-M.; Chang H.-C.; Hu T.-H.; YU-JEN FANG ; CHANG-CHUAN CHAN ; Collaborators of the Taiwan Community-Based Integrated Screening Group | Gastroenterology | 6 | 7 | |
| 2017 | Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1 | JIA-HORNG KAO ; Yu M.-L.; Peng C.-Y.; Heo J.; Chu C.-J.; Chang T.-T.; Lee Y.-J.; Hu T.-H.; Yoon K.T.; Paik S.W.; Lim Y.S.; Ahn S.H.; Isakov V.; McPhee F.; Hu W.; Scott Swenson E.; Yin P.D.; Treitel M. | Journal of Gastroenterology and Hepatology (Australia) | 16 | 12 | |
| 2020 | East Asia expert opinion on treatment initiation for chronic hepatitis B | JIA-HORNG KAO ; Hu T.-H.; Jia J.; Kurosaki M.; Lim Y.-S.; Lin H.-C.; Sinn D.H.; Tanaka Y.; Wai-Sun Wong V.; Yuen M.-F. | Alimentary Pharmacology and Therapeutics | 39 | 32 | |
| 2005 | Effects of concentrated ambient particles on heart rate variability in spontaneously hypertensive rats | Chang C.-C.; Hwang J.-S.; CHANG-CHUAN CHAN ; Wang P.-Y.; Hu T.-H.; TSUN-JEN CHENG | Journal of Occupational Health | 23 | 22 | |
| 2004 | Effects of concentrated ambient particles on heart rate, blood pressure, and cardiac contractility in spontaneously hypertensive rats | Chang C.-C.; Hwang J.-S.; CHANG-CHUAN CHAN ; Wang P.-Y.; Hu T.-H.; TSUN-JEN CHENG | Inhalation Toxicology | 43 | 40 |  |
| 2018 | Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV | CHUN-JEN LIU ; Chuang W.-L.; Sheen I.-S.; Wang H.-Y.; Chen C.-Y.; Tseng K.-C.; Chang T.-T.; Massetto B.; Yang J.C.; Yun C.; Knox S.J.; Osinusi A.; Camus G.; Jiang D.; Brainard D.M.; McHutchison J.G.; Hu T.-H.; Hsu Y.-C.; Lo G.-H.; Chu C.-J.; Chen J.-J.; Peng C.-Y.; Chien R.-N.; PEI-JER CHEN | Gastroenterology | 92 | 82 | |
| 2021 | Elimination of Hepatitis C Virus in a Dialysis Population: A Collaborative Care Model in Taiwan | Hu T.-H.; Su W.-W.; Yang C.-C.; Yang C.-C.; Kuo W.-H.; Chen Y.-Y.; Yeh Y.-H.; Chen S.-S.; Tsao Y.-Y.; Chen K.-M.; Yan S.-L.; Lai J.-H.; Yao C.-D.; Lim C.-H.; Jen H.H.; Yeh Y.-P.; Chen S.L.-S.; Chen, Tony Hsiu Hsi ; Chen S.-C.; Changhua Hepatitis C Elimination Task Force | American Journal of Kidney Diseases | 19 | 16 | |
| 2014 | Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan | Yeh Y.-P.; Hu T.-H.; Cho P.-Y.; Chen, Tony Hsiu Hsi ; Yen A.M.-F.; Chen S.L.-S.; Chiu S.Y.-H.; Fann J.C.-Y.; Su W.-W.; Fang Y.-J.; Chen S.-T.; San H.-C.; Chen H.-P.; Liao C.-S. | Hepatology | 65 | 59 | |
| 2016 | Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients | TUNG-HUNG SU ; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; SHIH-JER HSU ; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; TAI-CHUNG TSENG ; CHI-LING CHEN ; JIA-HORNG KAO ; the C-TEAM study group; the Taiwan Liver Diseases Consortium | Liver International | 158 | 149 | |
| 2014 | Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-naïve Taiwanese patients with chronic hepatitis B | Chien R.-N.; Peng C.-Y.; JIA-HORNG KAO ; Hu T.-H.; Lin C.-C.; Hu C.-T.; Chen C.-Y.; Hsieh T.-Y.; Lin H.-C.; Chuang W.-L. | Journal of Gastroenterology and Hepatology (Australia) | 9 | 8 | |
| 2016 | Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus | Chuang W.-L.; Chien R.-N.; Peng C.-Y.; Chang T.-T.; Lo G.-H.; Sheen I.-S.; Wang H.-Y.; Chen J.-J.; Yang J.C.; Knox S.J.; Gao B.; Garrison K.L.; Mo H.; Pang P.S.; Hsu Y.-C.; Hu T.-H.; Chu C.-J.; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 24 | 20 | |
| 2021 | Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease | Chuang W.-L.; Hu T.-H.; Buggisch P.; Moreno C.; Su W.-W.; Biancone L.; Camargo M.; Hyland R.; Lu S.; Kirby B.J.; Dvory-Sobol H.; Osinusi A.; Gaggar A.; Peng C.-Y.; CHEN-HUA LIU ; Sise M.E.; Mangia A. | The American journal of gastroenterology | 7 | 6 | |
| 2011 | Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses | Yeh M.-L.; Hung C.-H.; Huang J.-F.; CHUN-JEN LIU ; Lee C.-M.; Dai C.-Y.; Wang J.-H.; Lin Z.-Y.; Lu S.-N.; Hu T.-H.; Yu M.-L.; JIA-HORNG KAO ; Chuang W.-L.; PEI-JER CHEN ; DING-SHINN CHEN | PLoS ONE | 19 | 15 | |
| 2016 | A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection | JIA-HORNG KAO ; Chien R.-N.; Chang T.-T.; Peng C.-Y.; Hu T.-H.; Lo G.-H.; Wang H.-Y.; Chen J.-J.; Yang J.C.; Knox S.J.; Han L.; Mo H.; Mathias A.; Brainard D.M.; Sheen I.-S.; Hsu Y.-C.; Chu C.-J.; Chuang W.-L. | Liver International | 25 | 25 | |
